Katie Kramer on Muck Rack

Katie Kramer

Verified
New York
As seen in: Squawk Box, Versant Media, CNBC, NBC News, Yahoo, Bloomberg Law, Law360, Daily Camera, JD Supra, New York Upstate, Lexology, WARC and
@CNBC Supervising Producer and native Clevelander. Hear me on #SquawkPod daily. Watch @SquawkCNBC weekdays 6-9am ET.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Katie

Contact Katie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Colorado’s legacy of giving lives on in this year’s graduates (Opinion)

|
By Katie Kramer , Hanna Skandera
| Daily Camera
Getting your Trinity Audio player ready... By Katie Kramer and Hanna Skandera Each spring across Colorado, something remarkable happens. In stadiums, gyms or open fields, graduates step forward to receive their diplomas. What looks like a celebration of individual achievement is, in truth, something much bigger. It is a visible expression of Colorado generosity in action, a reminder that no one reaches that stage alone.
Open in Who Shared Issue with article?

US Entities Have Strategies to Defeat Asset-Tracing Subpoenas Original

|
By Katie Kramer , Hannah Miller
| Bloomberg Law
US financial institutions have several ways to limit or defeat asset-tracing subpoenas brought under Section 1782. • Recent doctrinal developments on post-judgment discovery have emerged in the Second Circuit. • Subpoena targets can expose speculative “for use” theories, insist on jurisdictional limits, and invoke proportionality.
Open in Who Shared View Duplicates (2) Issue with article?

FDA to publish guidance to improve the Rx to OTC switch application process

|
By Heidi Forster Gertner, Elizabeth Jungman, Eman Al-Hassan, Katie Kramer 
| hoganlovells.com
The pressure is building for the U.S. Food and Drug Administration (FDA) to take steps to facilitate making more drugs available over-the-counter (OTC) that currently require a prescription. As part of the Congressional funding reauthorization legislation for the OTC monograph user fee program (OMUFA II), FDA is now required to provide guidance that improves the process for companies to switch their New Drug Application (NDA) approved products from prescription, or Rx, to nonprescription, or OTC.
Open in Who Shared Issue with article?
See all 50 articles

Actions

Share this page

Get in touch with Katie

Contact Katie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified